Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models

Acta Pharmacologica Sinica

Volumn 30, Issue 5, 2009, Pages 617-627

  Zheng, Fei Qun ^a   Xu, Yin ^b,c   Yang, Ren Jie ^a   Wu, Bin ^c   Tan, Xiao Hua ^d   Qin, Yi De ^b   Zhang, Qun Wei ^c  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cancer gene therapy; Conditionally replicative adenovirus; Hepatocellular carcinoma; Herpes simplex virus thymidine kinase; Suicide gene therapy

Indexed keywords

E1A PROTEIN; GANCICLOVIR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 66749163693     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.33     Document Type: Article

References (26)

1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocelluar carcinoma. Hepatology 2002; 35: 519-24.
3. Chen SH, Kosai KI, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, et al. Combination suicide and cytokine gene therapy for hepatic matastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 3758-62.
4. Kieback DG, Fischer DC, Engehausen DG, Sauerbrei W, Oehler MK, Tong XW, et al. Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ter 2002; 9: 478-81.
5. Qiu Z, Harms JS, Zhu J, Splitter GA. Bovine Herpes virus teguyment protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol 2004; 78: 4224-33.
6. Mizuguchi H, Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ter 2002; 9: 236-42.
7. Kagaya T, Nakamoto Y, Sakai Y, Tsuchiyama T, Yagita H, Mukaida N, et al. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ter 2006; 13: 357-66.
8. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, et al. Suicide gene therapy with adenoviral delivery of HSV-tk gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ter 2007; 15: 834-40.
9. Finocchiano LME, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 2008; 15: 165-72.
10. Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther 2008; 15: 173-82.
11. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SLC. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ter 2003; 10: 1241-7.
12. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 2007; 7: 191-201.
13. Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T, et al. Direct and distant antitumor efects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Ter 2008; 15: 315-22.
14. Uchino J, Takayama K, Harada A, Yosuke K, Hiroyuki I, Curiel DT, et al. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Ter 2005; 12: 737-48.
15. Tan XH, Wan YH. Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Human Immunol 2008; 69: 32-34
16. Chou J, Chou TC. Quantifcation of synergism and antagonism of two or more drugs by computerized analysis. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego (CA): Academic Press; 1991. p223-244.
17. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207-16.
18. Chou TC, Talalay P. Quantitative analysis of dose-efect relationships: the combined efects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
19. Yao X, Yoshioka Y, Eto Y, Morishige T, Okada Y, Mizuguchi H, et al. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem Biophys Res Commun 2007; 362: 419-24.
20. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efcacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ter 1999; 6: 57-62.
21. Wilder O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410-3.
22. Wilder O, Morris JC. Terapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med 2000; 2: 353-60.
23. Raki M, Hakkarainen T, Bauerschmitz GJ, Särkioja M, Desmond R, Kanerva A, et al. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ter 2007; 14: 1380-8.
24. Wilder O, Morris JC. Te role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efcacy and toxicity. Cancer Res 2000; 60: 4167-74.
25. Lambright ES, Amin K, Wiewrodt R, Force1 SD, Lanuti1 M, Propert KJ, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efcacy. Gene Ter 2001; 8: 946-53.
26. Morris JC, Wilder O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ter 2000; 1: 56-62.